Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02919436
Other study ID # IRB #4742
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 2016
Est. completion date November 2020

Study information

Verified date January 2022
Source MaineHealth
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomization (1:1) of male patients, over age 50, undergoing elective spine surgery to tamsulosin versus a placebo.


Description:

Postoperative urinary retention (POUR) is a common complication following certain surgical operations. While much is known about the innervation and neural regulation of bladder emptying and storage, the cause of urinary retention after surgery is not fully understood. Early research has indicated that a small dose of tamsulosin (Flomax®), a commonly used medication approved to treat urinary symptoms in men with benign prostatic hypertrophy, may reduce the incidence of POUR. Urinary retention is a prevalent issue in patients undergoing spinal surgery, leading to patient discomfort and prolonged length of stay. We hypothesize that the use of perioperative tamsulosin in patients undergoing spinal surgery will decrease the incidence of POUR. The study is a prospective, double-blind, randomized, placebo-controlled trial. Subjects will be randomized 1:1 to receive either oral tamsulosin 0.4 mg or placebo, taken once each evening, beginning 5 days prior to surgery and continuing through the first postoperative day. The primary endpoint is met when the patient is able to spontaneously empty their bladder post-operatively, or needs to be catheterized with either a straight or indwelling urinary catheter for post-operative urinary retention, whichever occurs first.


Recruitment information / eligibility

Status Completed
Enrollment 610
Est. completion date November 2020
Est. primary completion date January 2020
Accepts healthy volunteers No
Gender Male
Age group 50 Years to 85 Years
Eligibility Inclusion Criteria - Male patient age 50 - 85 years - Undergoing elective spine surgery at least 5 days after enrollment - Preop visit done at office practice Exclusion Criteria: - Currently on tamsulosin or other alpha-adrenergic blocking drug - Allergy to tamsulosin - Allergy to lactose - Serious or life-threatening allergy to sulfa drugs - Emergent procedure - History of spinal trauma, spinal infection or spinal cord tumor - Pre-existing indwelling urinary catheter - History of orthostatic hypotension or current orthostatic hypotension - History of prostate, urethral or bladder surgery - Renal failure - Non-English speaking - Unable to provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tamsulosin
Active drug
Placebo
Lactose-filled capsules identical to active drug

Locations

Country Name City State
United States Maine Medical Center Portland Maine

Sponsors (2)

Lead Sponsor Collaborator
Anand Rughani, MD MaineHealth

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients Who Undergo Postoperative Catheterization for Urinary Retention Postoperative urinary retention was defined as the need for any postoperative urinary catheterization for acute retention. Per hospital protocol, failure to void 6 hours after surgery or development of bladder discomfort required bladder scan. If bladder volume exceeded 300 cc, catheterization was performed. Within 2 days after surgery
Secondary Length of Stay Length of hospital stay 0-7 days after surgery
Secondary Number of Participants With or Without Postoperative Urinary Retention Based on Preoperative Post-void Residual Was post-void residual greater than 50 cc when measured at the preoperative office visit associated with postoperative urinary retention? Within 2 days after surgery
See also
  Status Clinical Trial Phase
Terminated NCT02684344 - Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention N/A
Not yet recruiting NCT05941806 - Prophylactic Use of Tamsulosin in the Prevention of Post-operative Urinary Retention in Men After Rectum Resection Phase 3